Effectiveness and safety of ShenXiong glucose injection for acute ischemic stroke: a systematic review and GRADE approach by Xue-ting Liu et al.
RESEARCH ARTICLE Open Access
Effectiveness and safety of ShenXiong
glucose injection for acute ischemic stroke:
a systematic review and GRADE approach
Xue-ting Liu, Peng-wei Ren, Le Peng, De-ying Kang*, Tian-le Zhang, Shu Wen, Qi Hong and Wen-jie Yang
Abstract
Background: To appraise critically whether published trials of ShenXiong glucose injection for patients with acute
ischemic stroke (AIS) are of sufficient quality, and in addition to rate the quality of evidence by using the GRADE
approach (grading of recommendations, assessment, development, and evaluation, GRADE).
Methods: A literature search was performed in the Cochrane Library, MEDLINE, EMBASE, CBM, Chinese TCM
(traditional Chinese medicine) Database, CNKI, VIP, WanFang Databases until January 2015. The limits were patients
with AIS and randomized controlled trials (RCTs) or quasi-RCTs. Studies by which patients suffering intracerebral
haemorrhage were excluded.
Results: Twelve studies fulfilled the inclusion criteria. We found significant benefits of ShenXiong glucose injection
compared with conventional treatment in improving activities of daily living function at 4 weeks (MD = 34.12, 95 % CI:
29.07, 39.17), neurological function deficit at 2 weeks (MD = −5.39, 95 % CI: −6.90, −3.87), 4 weeks (MD = −5.16,
95 % CI: −6.49, −3.83), and clinical effects at 4 weeks (RR = 1.17, 95 % CI: 1.10, 1.24). No trials reported the effects
of ShenXiong glucose injection on the risk of early, deterioration, or quality of life. No adverse events were reported
within the whole follow-up period.
Conclusions: The use of ShenXiong glucose injection may improve rehabilitation for patients with acute ischemic
stroke, however, as the GRADE approach indicated low to moderate quality of available evidence as well as insufficient
information about harm and patients preference, the recommendations were not provided for ShenXiong glucose
injection taking as a therapeutic intervention to patients with acute ischemic stroke.
Keywords: ShenXiong glucose injection, Acute ischemic stroke (AIS), Systematic review (SR), GRADE
Background
Stroke occurs when the blood supply to the brain is
interrupted or reduced, which may be caused by blocked
arteries or leaking and bursting of blood vessels [1]. This
deprives the brain of the supply of oxygen and nutrients,
causing damage to the brain tissue [2]. Being one of the
most severe neurological diseases, stroke often leads to
death or gross physical impairment or disability [2], and
the morbidity of stroke continues to rise with an annual
increase of 8.1 %. Although the incidence of stroke is
declining in many developed countries, the absolute
number of stroke patients continues to enlarge because
of the ageing population [3]. Of those, acute ischemic
stroke as the dominant type of stroke, account for 85 %
of all strokes [4].
Currently, rapid assessment and early intervention for
patients suffering an acute ischemic stroke is of top pri-
ority [5, 6]. There is as yet no routine, effective, generally
accepted, specific treatment for AIS, except for aspirin
[7] and anti-thrombolysis with tissue plasminogen acti-
vator approved by FDA of US is administered in the
setting of AIS within 4.5 h from symptom-onset [8–10].
Therefore, it is necessary to test other promising thera-
peutic approaches to acute ischemic stroke [11, 12]. The
lack of effective and widely applicable pharmacological
treatments for acute ischemic stroke patients leads to a
growing interest in Chinese traditional medicine [13, 14],
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for which extensive observational and anecdotal experi-
ence has accumulated over the past one thousand years
[14, 15]. Of those, Chinese herbal medicine is the most ad-
dressed in China, US and European Union [12, 13]. In
China, a series of optional treatments for treating AIS are
available. Traditional Chinese medicine have proven to be
effective complementary intervention for AIS, of which
Chinese herb products are still prevailing well and make a
significant difference [12, 14, 15]. The overall treatment
concept for Chinese traditional medicine is different
from Western medicine, and herb medicines were al-
ways used to treat acute ischemic stroke. ShenXiong
glucose injection is one of the most widely used Chinese
herb medicine.
ShenXiong glucose injection (also named as Danshen-
Chuanxiongqin injection) has properties that might be
effective in acute ischemic stroke [16], it is on the na-
tional essential drug list of China as a new drug for
cardio-cerebral vascular diseases. ShenXiong glucose in-
jection is a compound preparation, made up of Salvia
miltiorrhiza and Ligustrazine [16]. Of those, fifteen kinds
of biologically active substances have been extracted
from the dried roots of Salvia miltiorrhiza, a traditional
medical herb known as Danshen, among which tanshi-
none, isotanshinone and hydroxy-tanshinone are the im-
portant ingredients [16, 17]. Various studies suggested
that Danshen could decrease intracranial pressure by de-
creasing overall water content of the brain and cerebro-
spinal fluid volume, and by reducing blood volume due
to vasoconstriction [18, 19]. DanShen may also improve
cerebral perfusion by decreasing viscosity. It is reported
to increase coronary blood flow, suppress thromboxane
formation, decrease cerebral oedema, infarct size and
neurological deficit [19]. It is always used either alone or
in combination with other herbal ingredients for patients
with coronary heart diseases, hyperlipidemia, cerebro-
vascular diseases. In both China and other countries like
US, such findings come either from biomedical studies
[19] or from clinical trials [19, 20]. Ligustrazine, a bio-
active ingredient extracted from Chuanxiong (Rhizoma
Chuanxiong), was also proved to have beneficial effect
on cerebrovascular diseases in pharmacological studies
[21]. ChuanXiong could improve brain microcirculation
by preventing thrombus formation and platelet aggrega-
tion and blood viscosity in order that it might have
significant beneficial effects in the treatment of acute
ischemic stroke [21]. As the compound of Salvia miltior-
rhiza and ligustrazine, ShenXiong glucose injection has
been widely accepted as a standard treatment for acute
ischemic stroke in China for over 15 years [16]. Its
mechanism is associated with exciting histamine recep-
tors, improving neuron function and reducing serum
total cholesterol-triglyceride levels, increasing serum
high density lipoprotein levels, and enhancing tissue
plasminogen activator activity. Moreover, ShenXiong
glucose injection can prevent free radical injury from
ischemic brain tissue by reducing lipid peroxide [16].
Currently there are a large number of studies of the
clinical efficacy of ShenXiong glucose injection in acute
ischemic stroke published in the global, especially in
China. However, those clinical trials have not been
reviewed systematically at present, whether the existing
evidence is of sufficient scientifically rigorous and whether
ShenXiong glucose injection can be recommended for
routine use based on current evidence is still uncertain.
To make specific recommendations for further research
into the effectiveness and safety of ShenXiong glucose in-
jection for patients with acute ischemic stroke, we carry
out a systematic review and GRADE approach in twofold:
(i) to systematically review all the randomized and quasi-
randomized controlled trials of ShenXiong glucose injec-
tion for acute ischemic stroke; (ii) in addition, to evaluate
the quality of current evidence by the use of GRADE sys-
tem, and to provide the best available evidence for clinical
practice.
Methods
Criteria for considering studies for this review and GRADE
approach
Type of studies
We included all randomized controlled trials (RCTs), and
quasi-randomized controlled trials (trials that used a non-
random method of treatment allocation, e.g. hospital
number, date of birth or day of the week), either published
or unpublished.
Types of participants
Trials involving patients of any age or sex with apparent
acute ischemic stroke (excluding intracerebral hemorrhage)
were eligible. Stroke must be diagnosed in accordance with
the diagnostic criteria of neuro-imaging verification of
pathos-logical alterations in the brain, with computed tom-
ography (CT) or Magnetic Resonance Imaging (MRI). Of
these criteria, “Key Points for Diagnosing Cerebrovascular
Diseases” and “Stroke diagnosis curative standard” modi-
fied in the 4th National Cerebrovascular Disease Seminar
by the China Medical Society in 1995 [22] and “Guidelines
of diagnosis and treatment of Chinese acute ischemic
stroke” in 2010 [23], were adapted.
Type of interventions
Regardless of frequency, intensity or the duration of treat-
ment, either ShenXiong glucose injection versus placebo
or ShenXiong injection plus conventional treatments ver-
sus conventional treatments alone were included in this
review and GRADE approach.
Any other routine treatments except ShenXiong glucose
injection, such as antihypertensive, anti-platelet aggregation
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and other symptomatic treatments if necessary, were
defined as conventional treatment, and all participants
either in experimental group or in controlled group
would receive same conventional treatments during
whole trial period.
Type of outcome measures
The primary outcome is death or dependency at the end
of scheduled follow-up. Dependency is defined as se-
verely dependent on others in activity of daily living,
based on the definition of the Barthel Index scores 60 or
less, or an Oxford handicap grade 3 to 6.
Secondary outcomes were: (1) Changes of neuro-
logical deficit after ShenXiong glucose injection treat-
ment and at the end of scheduled follow up. The
measures could concentrate on specific impairment
(for instance, Motricity Index, Motor Assessment Scale)
or global neurological deficit (for instance, the National
Institute of Health Stroke Scale or the Neurological
Function Deficit Score). The clinical neurological im-
pairment score of stroke patients is measured by the
National Institute of Health Stroke Scale (NIHSS) or
the Neurological Function Deficit Score (NFDS) . The
neurological function deficit score changes, such as
NFDS reduction rate over 18 % was taken as curative
effect standard [24]; (2) Quality of life (QOL) at the
end of follow up, which is measured by the Nottingham
Health Profiles or Spiter Quality of Life Index; (3) Ad-
verse events including bleeding, dizziness, vomiting,
allergic reaction, or other adverse events caused by
ShenXiong glucose injection. The number of patients




We searched the Cochrane Central Register of Controlled
Trials (CENTRAL, Ovid, from 1991 to January 2015),
MEDLINE (PubMed, from 1966 to January 2015),
EMBASE (Ovid, from 1966 to January 2015), CBM
(Chinese Biomedicine Database, from 1978 to January
2015), Chinese TCM Database (from 1949 to January
2015), CNKI (China National Knowledge Infrastructure,
until January 2015), VIP (Chinese Scientific Journal
Database from 1989 to January 2015), WanFang Data-
base (from 1998 to January 2015). The key words com-
prise DanshenChuanxiongqin, Danshen-Chuanxiongqin,
ShenXiong glucose injection, Dan Xiong and ShenXiong
injection were used as English and corresponding Chinese
search terms to identify studies from aforementioned da-
tabases. Reference lists of all included studies were also
searched for publications that meet the inclusion criteria.
Searching other resources
In order to search all the related studies, we also hand-
searched the following relevant journals of TCM (the last
issues were set at January 2015): World Journal of
Integrated Traditional and Western Medicine, Chinese
Journal of Integrative Medicine, Journal of Chinese Inte-
grative Medicine, Journal of Traditional Chinese Medicine
and Journal of Beijing University of Traditional Chinese
Medicine.
Data collection and analysis
Selection of studies
Clinical trials were identified by screening the titles
and abstracts of targets by two independent reviewers
(XL, LP), and any disagreements were resolved through
discussion and consultation with a third reviewer (DK).
Data extraction and management
Two reviewers (XL, LP) independently extracted data
from studies that met the inclusion criteria using a
pre-designed form, and disagreements were resolved
by discussing with the third reviewer (DK). We
planned to retrieve the following data: methods (study
design and execution, method of randomization), par-
ticipant characteristics (number of patients, age, sex,
inclusion criteria, method of diagnosis), interventions
(description of interventions given to each treatment
group including, with or without other combined
treatment), outcomes, methods of analysis (intention-
to-treatment analysis or per-protocol analysis, or both)
and statistical methods used.
Assessment of risk of bias in included studies
Two reviewers (XL, LP) independently assessed the meth-
odological quality of each included studies using the “risk
of bias” assessment tool outlined in the Cochrane Hand-
book for Systematic Reviews of interventions (Version
5.1.0) [25]. Any disagreements were resolved by discussion
with the third reviewer (DK).
Statistical analysis
The Cochrane Review Manager software, RevMan 5.1
[26], was used to calculate treatment effects across trials.
For discontinuous data, we used relative risk (RR) with
the corresponding 95 % confidence interval (CI) as the
measure of effect. For continuous data, the measure of
the treatment difference for any outcome would be the
mean difference (MD) when the pooled trials using the
same rating scale or test, otherwise, the standardized
mean difference (SMD) with 95 % confidence interval
(CI) would be used. A Chi-square based test of homo-
geneity was performed using Cochrane Q statistic [27]
and I2. If P value less than 0.10 or I2 value exceed 50 %
substantial, indicated heterogeneity among trial results
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significantly, we would carry out a subgroup analysis to
explore the sources of heterogeneity, including clinical
heterogeneity, such as the route of administration, time
and dose interval of start of treatment, type of interven-
tion, as well as the methodological heterogeneity, such
as design type of the trials, the risk bias of happening
and so on. If I2 was less than or equal to 50 % we would
use a fixed-effect meta-analysis, otherwise, if the under-
line true effect being assumed to follow up a normal
distribution, we would use a random-effects model (in
which case the confidence intervals will be broader
than those of a fixed-effect model). Sensitivity analysis
was carried out by using the leave-one-out approach to
explore the influence of heterogeneity, to determine
how robust the results of analysis were. Funnel plots
and Egger analysis were used to assess the existence of
publication bias, if possible.
Besides, in the process of interpreting results and com-
ing to conclusions, we planned to use GRADE approach
(grading of recommendation assessment, development,
and evaluation, GRADE) to evaluate the quality of evi-
dence. This approach is a systematic method for
evaluating quality of evidence and formulating strength
of recommendation if sufficient information is available
[28]. Firstly, we subsequently classified the importance
of each outcome. Three categories of outcome were
specified based on their importance (median score of 1
to 9). Then the quality of evidence is divided into four
categories: high, moderate, low, and very low. The
GRADE approach defines clearly the methodological cri-
teria by which evidence can be upgrade or downgrade
and the justification for the strength of recommendation
being formulated as “strong” or “weak”. Critical and im-
portant outcomes were used for decision making and




A flow diagram of study selection is shown in Fig. 1.
After initially identifying 2949 articles, 12 studies that
met the inclusion criteria were included for this review

















Records after duplicates removed (n=2557)
Included studies for review (n=12)
Full text articles assessed for eligibility (n=12)
Records screened (n=27) Exclusion (n=15)
Not randomized (n=3);
Insufficient data (n=1);
Not meet participants (n=2);
Not meet interventions (n=8);
Not meet outcomes (n=1);
Exclusion (n=2530)
Not randomized (n=2);
Animal or lab studies (n=6);
Non-relevant articles (n=2522);
Fig. 1 Flow chart of study selection. Abbreviations: CBM, Chinese Biomedical Literature Database; CNKI: China National Knowledge Infrastructure;
VIP: Chinese Scientific Journals Database; WJITWM: World Journal of Integrated Traditional and Western Medicine; CJIM: Chinese Journal of
Integrative Medicine; JCIM: Journal of Chinese Integrative Medicine; JTCM: Journal of Traditional Chinese Medicine; JBUTCM: Journal of Beijing
University of Traditional Chinese Medicine
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Table 1 Characteristics of included studies
First author Number of
patients (n)






Dose of Experiment Conventional measure (CM) Setting
E C E C E C
Wang 2014 [32] 35 35 67.24 ± 4.38 68.15 ± 5.0 CT,MRI ≤3d 18.15 ± 8.14 17.96 ± 8.02 Danshen Ligustrazine




Liu 2014 [30] 71 71 53.1 ± 1.7 49.7 ± 2.1 CT,MRI ≤3d 22.49 ± 1.21 23.18 ± 1.74 Danshen Ligustrazine
13–15 ml/d + 250 ml glucose + CM
antihypertensive, reduce ICP Inpatients










Huang 2012 [40] 38 30 64.3 ± 5.6 66.3 ± 5.3 CT,MRI NR NR NR ShenXiong glucose 200 ml plus CM nutrition brain cells, reduce ICP Inpatients
Zhou 2011 [34] 40 40 42–75 42–75 CT,MRI NR 22 ± 10 23 ± 10 ShenXiong glucose 200 ml plus CM antihypertensive, reduce ICP Inpatients
Shan 2013 [31] 30 30 65 64 CT,MRI ≤3d 22.50 ± 8.03 21.65 ± 6.2 ShenXiong glucose 200 ml plus CM antihypertensive, anti platelet
aggregation
Inpatients
Zhe 2011 [33] 30 31 57.34 ± 8.97 58.26 ± 7.48 CT,MRI ≤2d 24.63 ± 9.28 23.68 ± 7.89 ShenXiong glucose 200 ml plus CM nutrition brain cells, reduce ICP,
anti-platelet aggregation
Inpatients





Guan 2011 [42] 46 40 63 ± 3 63 ± 3 CT,MRI NR NR NR ShenXiong glucose 200 ml plus CM reduce ICP, nutrition brain cells Inpatients
Nie 2013 [35] 35 35 55–71 54–70 CT,MRI NR 25.63 ± 9.08 24.68 ± 7.59 ShenXiong glucose 200 ml plus CM anti platelet aggregation,
nutrition brain cells
Inpatients























Study characteristics and quality assessment
Characteristics of the 12 trials included in this review were
summarized in Table 1, the number of participants that
received ShenXiong glucose injection treatment ranged
from 30 to 71 (total 494), and the number of participants
in the control groups ranged from 30 to 71 (total 480). In
12 studies, ShenXiong glucose injection plus conventional
therapy was administered in experimental group, the
dose of Danshen-Chuanxiongqin ranges from 10 ml/d
to 15 ml/d, and the duration of treatment ranged from
2 to 4 weeks.
The results of the quality assessment of the included
studies are shown in Table 2. Two studies [30, 31] had low
selection bias (allocating group by using random number
table), two studies [32, 33] were quasi-randomized trials,
other 8 trials reported “randomly allocating” participants,
but not stated the method of randomization. Possible per-
formance bias from inappropriate blinding of participants
and personnel might be present in 12 studies.
Effects of interventions
Death or dependency at the end of scheduled
follow up period
No deaths were reported within the period of treatment
in 12 trials. This may mean that only mild strokes were
included in the trials or that death occurred were not re-
ported by trialists.
A measure of activities of daily living function was
assessed in five [31–35] of the included trials. Barthel
index scores was measured at 1 week in only one trial
[32], 2 weeks in two studies [32, 34], and 4 weeks on
treatment in four studies [31–33, 35]. All of these trials
reported sufficient information to allow for inclusion
into a meta-analysis. Wang 2014 reported no significant
difference on Barthel index score in patients randomized
to ShenXiong glucose injection group as compared with
control group, by approximately 7 days (MD = 4.65, P =
0.14, 95 % CI: −1.56, 10.86); Two studies [32, 34] re-
ported Barthel index score at 14 days, however, a pooled
analysis was not performed since severe heterogeneity
were detected between the trials (P = 0.02, I2 = 82 %),
which was possibly due to differences in outcome mea-
surements used and types of treatment. The trial by
Zhou 2011 reported that there was significant difference
in the Barthel index scores at 14 days in the ShenXiong
glucose injection group as compared with control group
(MD = 18.00, 95 % CI: 11.43, 24.57). Trial by Wang 2014
reported no significant difference in the daily activities
score at four weeks between the treatment groups
(MD = 6.08, 95 % CI: −1.19, 13.35), but the confidence
interval was very wide and included clinically signifi-
cant effects in both directions (Fig. 2).
Four studies [31–33, 35] also assessed Barthel index
scores at 28 days of treatment, however a pooled analysis
was not performed since severe heterogeneity were de-
tected among the trials (I2 = 90 %), which was possibly
due to the differences in term of outcome measurements
used and types of treatment. All of these trials reported
higher Barthel scores at 28 days for the ShenXiong glucose
injection group as compared with control group. We per-
formed a subgroup analysis based on the treatment type
(ShenXiong glucose injection [31, 33, 35] and Danshen
ligustrazine injection [32]). There were significant differ-
ence in improvement of activities of daily living function















Wang 2014 [32] sequence of
entering the group
Unclear Unclear Unclear Yes Yes Unclear
Liu 2014 [30] random number
table
Unclear Unclear Unclear No Unclear Unclear
Liu 2011 [39] unclear Unclear Unclear Unclear Yes No Unclear
Zhou 2013 [37] unclear Unclear Unclear Unclear No Yes Unclear
Huang 2012 [40] unclear Unclear Unclear Unclear Yes Unclear Unclear
Zhou 2011 [34] unclear Unclear Unclear Unclear Yes Yes Unclear
Shan 2013 [31] random number
table
Unclear Unclear Unclear Yes Yes Unclear
Zhe 2011 [33] sequence of
entering the group
Unclear Unclear Unclear Yes Yes Unclear
Ling 2013 [41] unclear Unclear Unclear Unclear Yes Unclear Unclear
Guan 2011 [42] unclear Unclear Unclear Unclear No Unclear Unclear
Nie 2013 [35] unclear Unclear Unclear Unclear Yes Unclear Unclear
Lin 2014 [36] unclear Unclear Unclear Unclear Yes Unclear Unclear
Annotation: Yes = low risk of bias; No = high risk of bias; unclear = uncertain risk of bias
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at 28 days in the ShenXiong glucose injection group com-
pared with control group (MD= 34.12, 95 % CI: 29.07,
39.17); as well as in the Danshen ligustrazine injection
group compared with control group (MD= 10.24, 95 % CI:
3.10, 17.38) (Fig. 3).
Improvement of neurological function deficit after
treatment and at the end of scheduled follow up
Seven trials [30–36] with a total of 821 patients mea-
sured improvement of neurological function deficit
after ShenXiong glucose injection treatment by using
Fig. 2 A random effects Meta-analysis on improvement of activities of daily living function of ShenXiong glucose injection
Fig. 3 Subgroup analysis. ShenXiong glucose injection vs DanShen ligustrazine injection; Outcome: Improvement of activities of daily living function at
4 weeks follow-up
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continuous approaches, such as changes of neurological
deficit score. There was significant heterogeneity be-
tween studies [30, 32] (Chi-squared P = 0.10, I2 = 63 %),
which may be explained by the differences in outcome
measurements used and types of treatment, therefore,
the overall estimate of treatment effect should be inter-
preted with caution, although no significantly improve-
ment of neurological impairment (MD for neurological
improvement with ShenXiong glucose injection −2.37,
95 % CI −5.44 to 0.70) were observed at 7 days in the
ShenXiong glucose injection group compared with con-
trol group (Fig. 4).
Four trials [30, 32, 36, 37] assessed improvement of
neurological function deficit at 14 days on treatment,
as there was significant heterogeneity among studies
(Chi- squared P = 0.005, I2 = 77 %), which was possibly
due to the differences in outcome measurements used
and types of treatment. A subgroup analysis based on
the treatment type (ShenXiong glucose injection [36]
and Danshen ligustrazine injection [30, 32, 37]) indi-
cated that there were significant difference in improve-
ment of neurological function deficit at 14 days in the
ShenXiong glucose injection compared with control
group (MD = −3.60, 95 % CI: −4.88, −2.32), as well as in
the Danshen ligustrazine injection group compared
with control group (MD = −6.01, 95 % CI: −6.51, −5.50)
(Fig. 5).
Four studies [31–33, 35] also assessed the improvement
of neurological function deficit at 28 days. A pooled ana-
lysis of these studies found a significant difference in the
neurological function deficit scores at 28 days between the
treatment groups (MD= −5.16, 95 % CI: −6.49, −3.83),
low level of heterogeneity was detected among the studies
(P = 0.31, I2 = 16 %) (Fig. 4).
Response rate
The response rate taken as a measure of clinical effects
was presented in eleven trials involving of 884 patients,
there was no statistically significant heterogeneity in
those studies (P = 0.81, I2 = 0 %). Meta-analysis of 11 tri-
als showed that ShenXiong glucose injection had signifi-
cantly higher response rate than that of control group
(RR = 1.17, 95 % CI: 1.10, 1.24) (Fig. 6).
Safety evaluation
Six trials clearly reported that there were no adverse
events during the trials, while the left studies failed to
report whether adverse events happening or not. The
meta-analysis didn’t perform due to numerical data for
the outcomes of interest were unavailable.
Fig. 4 A random effects Meta-analysis on neurological function deficit score of ShenXiong glucose injection
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Publication bias
A funnel plot analysis on response rate of 11 trials was
generated to explore the potential publication bias, and
it present asymmetric trend, indicated that potential
publication bias may exist in this review (Fig. 7).
The quality of evidence by using GRADE
In addition, we applied GRADE to grade the quality of
available evidence, regarding to this GRADE approach,
all 12 RCTs started out as high-quality evidence. Of
those, seven trials [30–36] reported the improvement of
Fig. 5 Subgroup analysis. ShenXiong glucose injection vs. DanShen ligustrazine injection; Outcome: Improvement of neurological deficit at 2 weeks
follow up
Fig. 6 A random effects Meta-analysis on response rate of ShenXiong glucose injection
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neurological function deficit score (NFDS), the quality of
the evidence was downgraded as moderate due to incon-
sistency and possible publication bias; Barthel index score
was taken as critical outcome measure in five RCTs
[31–35], the low quality was graded due to imprecision,
inconsistency, and significant heterogeneity; eleven stud-
ies evaluated clinical effects by the use of response rate,
and the evidence was set as moderate quality, publication
bias and the lack of directness were the main consider-
ations for downgrading (Table 3 and Additional file 1).
Discussion
Summary of main findings
This review was done in accordance with the methods
of a Cochrane systematic review. We identified and in-
cluded 12 trials involving a total of 974 participants. This
systematic review has shown that ShenXiong glucose in-
jection given as a treatment in the acute stage of ische-
mic stroke significantly effect on improving activities of
daily living function at 7 days, 14 days and 28 days
whilst on treatment, but a meta-analysis of this outcome
using data from the five studies was not performed due
to obvious heterogeneity among the study estimates. Sig-
nificant improvements on activities of daily living func-
tion were observed from individual trials’ results. We
performed subgroup analysis based on the type of treat-
ment (ShenXiong glucose injection and Danshen ligus-
trazine injection). No clear difference in Barthel index
score at 28 days was present between ShenXiong glucose
injection trial and Danshen ligustrazine injection trial.
None of the included studies reported the pre-specified
primary outcome of death during the follow-up period, it
may be explained that authors attempted to emphasize
short-term effect of ShenXiong glucose injection, or that
there were no deaths during the short-term follow up
period. Furthermore, pooled results showed ShenXiong
glucose injection had significant effect on the improvement
of neurological function deficit at 14-day and 28-day
whilst on treatment. But this results should be inter-
preted with caution because of severe heterogeneity
was seen among the review. We performed subgroup
analysis based on the type of treatment (ShenXiong glu-
cose injection and Danshen ligustrazine injection) to
explore the reasons for large heterogeneity. It showed
no evidence of difference in efficacy between ShenXiong
glucose injection and Danshen ligustrazine injection. There
is evidence that ShenXiong glucose injection has clinical
effects, such as higher response rate, this result is consist-
ent with the improvement of neurological function deficit.
Lastly, only six trials reported that no adverse events were
observed during the trials period, while the left studies
failed to report whether adverse events happening or not.
We cannot draw a conclusion on the safety of ShenXiong
glucose injection. There is currently not enough evidence
to determine whether the use of ShenXiong glucose injec-
tion in acute ischemic stroke would result in any harmful
effects.
After applying GRADE approach for this systematic
review, although rating down for the risk of bias was
not required, Unexplained heterogeneity was found
within included studies, while the available data did not
permit an interpretation as to the reason for some of
the inconsistencies we found, such inconsistency is also
a basis for downgrading the level of evidence to support
Fig. 7 Funnel plot analysis. Funnel plot analysis on response rate of the 11 trials comparing ShenXiong glucose injection with
conventional treatment
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Table 3 ShenXiong glucose injection plus conventional treatment compared to conventional treatment for acute ischemic stroke












Death none none none none none CRITICAL
NFDS Follow-up:
1–4 weeks
none The mean NFDS in the intervention
groups was -4.70 lower






NFDS - 1 week none The mean NFDS - 1 week in the
intervention groups was −2.37 lower
(−5.44 lower to 0.7 higher)
- 156 (2 studies) ⊕⊕⊝⊝ low
[1, 2]
CRITICAL
NFDS - 2 weeks none The mean NFDS - 2 weeks in the
intervention groups was −5.39 lower
(−6.90 to −3.87 lower)
- 378 (4 studies) ⊕⊕⊕⊝
moderate [3–6]
CRITICAL
NFDS - 4 weeks none The mean NFDS - 4 weeks in the
intervention groups was −5.16 lower
(−6.49 to −3.83 lower)
- 287 (4 studies) ⊕⊕⊕⊕ high
[7, 8]
CRITICAL
Barthel score none The mean Barthel score in the
intervention groups was 19.98 higher
(10.17 to 29.79 higher)




none The mean Barthel score - 1 week in the
intervention groups was 4.65 higher
(−1.56 lower to 10.86 higher)






none The mean Barthel score - 2 weeks in the
intervention groups was 12.14 higher
(0.47 to 23.82 higher)






none The mean Barthel score - 4 weeks in the
intervention groups was 28.09 higher
















736 per 1000 861 per 1000 (810 to 913)
Moderate
750 per 1000 878 per 1000 (825 to 930)
Patient or population: patients with acute ischemic stroke Settings: inpatients, Intervention: ShenXiong glucose injection plus conventional treatment,
Comparison: conventional treatment
aThe basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95 % confidence
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95 % CI)
CI Confidence interval
RR Risk ratio
GRADE Working Group grades of evidence
(⊕⊕⊕⊕) High quality: Further research is very unlikely to change our confidence in the estimate of effect
(⊕⊕⊕⊝) Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
(⊕⊕⊝⊝) Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
(⊕⊝⊝⊝) Very low quality: We are very uncertain about the estimate
[1] Heterogeneity test: P = 0.10, I2 = 63 %. Obvious inconsistency exists in only two studies
[2] Imprecision (large width of CI). Sample sizes and number of events less than the number of patients generated by a conventional sample size calculation for a
single adequately powered trial
[3] As the random sequence generation was not clearly described in only two of the trials, the overall risk of bias is not serious
[4] Heterogeneity test: P = 0.005; I2 = 77 %. The available data do not permit an interpretation as to the reason for some of the inconsistencies that were found.
Such inconsistency is also a basis for downgrading the level of evidence in support of ShenXiong glucose injection for AIS
[5] Although the sample sizes and number of events (n = 292) less than the number of patients generated by a conventional sample size (n = 300) calculation for
a single adequately powered trial, the change of our confidence for this outcome not serious, thus not downgrade
[6] The funnel plot present asymmetric trend
[7] Although the sample sizes and number of events (n = 287) less than the number of patients generated by a conventional sample size (n = 300) calculation for
a single adequately powered trial, the overall imprecision for this outcome is not serious, thus not to downgrade the quality of evidence for imprecision
[8] Heterogeneity: P = 0.02; I2 = 82 %. The available data do not permit an interpretation as to the reason for some of the inconsistencies that were found. Such
inconsistency is also a basis for downgrading the level of evidence
[9] Heterogeneity: P < 0.00001; I2 = 90 %. The available data do not permit an interpretation as to the reason for some of the inconsistencies that were found. Such
inconsistency is also a basis for downgrading the level of evidence
[10] The funnel plot present asymmetric trend on clinical efficacy, and the risk of publication bias may exist in somewhat
[11] Heterogeneity: (P = 0.39); I2 = 0 %, mild inconsistency maybe exists in 4 studies
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ShenXiong injection for AIS patients. In addition, regard-
ing the two important outcomes, the total number of
events or patients does not exceed the OIS (Optimal
Information Size), therefore, rating down for imprecision
was warranted [38]. By the way, the quality of evidence
was not reduced in concerning indirectness. And finally,
despite the fact that none of the included studies were
found by pharmaceutical industry, the funnel plot present
asymmetric trend on clinical efficacy, and the risk of pub-
lication bias may exist in somewhat.
Therefore, our GRADE approach leads to the decision
that ShenXiong glucose injection for a individual patient
with acute ischemic stroke should be approached cau-
tiously, patients‘values and preferences should be con-
sidered and allow them to participate in the medical
decision making process.
The limitations of the twelve trials assessed to be of
inferior methodological quality were as follows
1. Only two trials using a random method to divide the
groups, the remaining 10 trials reported ‘randomly allo-
cating’ participants but the method of randomisation
was not described. 2. None of the included trials re-
ported allocation concealment, and whether a blinding
method used or not within twelve trials is unclear, increas-
ing the risk of selection or performance bias happening. 3.
In addition, all included studies were conducted in China
and were published in Chinese journals. A funnel plot
analysis also indicated asymmetry trend for the outcome of
response rate, publication bias maybe exist, although we
attempt to perform comprehensive search as well as sup-
plementary search for both published and unpublished
literature. 4. Another limitation of the review relate to the
over-proportion of small trials to be included, may cause
imprecision and inconsistency of effect size among those
trials. Although the estimate of effect on the outcomes is
significant statistically, the observed effects could also sim-
ply be due to bias rather than to a biological effect of
ShenXiong glucose injection.
In addition, the usefulness of evidence was limited due
to the following reasons,. Firstly, the follow-up time was
insufficient to evaluate the long term effects of ShenXiong
glucose injection, in the 12 trials, follow-up time ranged
from 7 days (1 week) to 28 days (4 week) after the start of
treatment. Secondly, the reporting on adverse effect was
poor in most of included trials, it is highly implausible that
no adverse event happen among 494 patients, the safety of
ShenXiong injection is still inconclusive. And additional
limitations in this review include the diversity of outcome
measure used by the included studies, and the limited
duration of follow up (generally no more than 2 months).
In summary, the overall quality of evidence was judged
to be low to moderate due to important limitations exist
in study design, inconsistency, lack of directness, impreci-
sion and possible publication bias. The result of published
intervention trials are therefore of insufficient quality to
enable evidence-based recommendations to be developed
for clinical practice in acute ischemic stroke. This review
systematically describes current evidence from latitudinal
and longitudinal studies on ShenXiong glucose injection
and identifies methodological aspects to be improved in
further research. This methodological improvement is
pivotal for the assessment of the body of evidence on
ShenXiong glucose injection treatment. High-quality evi-
dence from methodologically via double-blinded random-
ized controlled trials are required to provide further
support for administration of ShenXiong glucose injection
for patients with acute ischemic stroke.
Conclusion
Implications for practice
The results of this review provided evidence to support
that the use of ShenXiong glucose injection may im-
prove rehabilitation for patients with acute ischemic
stroke, however, as the GRADE approach indicated low
to moderate quality of available evidence as well as insuffi-
cient information about harm and patients preference, the
recommendations for ShenXiong glucose injection for
treating patients with acute ischemic stroke were not pro-
vided in this context.
Implications for research
Further RCTs on ShenXiong glucose injection are needed
and should be reported according to the CONSORT
(Consolidated Standards for Reporting Trials, CONSORT)
statement. High quality on the reporting of trials is
strongly required.
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